ASKA Pharmaceutical Co., Ltd. Company Profile

Company Overview:

ASKA Pharmaceutical  is a Japan-based pharmaceutical company. The company operates in Japan and Germany.

The company develops in-house products such as Altat, H2 blocker for the treatment of digestive ulcers and gastritis. It also offers Lipidil, a treatment for hyperlipidemia, and Thyradin for the treatment of hypothyroidism.

ASKA promotes joint development with other Japanese and overseas companies and develops drugs such as L-105, a hepatic encephalopathy treatment with rifaximin as an active ingredient; AKP-501, a fertility treatment with follicle stimulating hormone (FSH) preparation of recombinant DNA origin as an active agent; and CDB-2914, a uterine leiomyomata treatment with ulipristal acetate as an active ingredient.

In addition, the company provides medical information through MR (medical representative) support information system, which allows to share necessary information and to respond to the changes in the pharmaceutical market.

Scope of the Report

• About the Company - Historical Details, Current Ownership Structure and basic overview of ASKA Pharmaceutical Co., Ltd. in terms of revenue, net income, and operating income.
• Financials - Details about ASKA Pharmaceutical Co., Ltd. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
• Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
• Company SWOT Analysis - Outlines ASKA Pharmaceutical Co., Ltd.’s strengths, weaknesses, and opportunities and threats facing the company.
• Recent Developments - Showcases ASKA Pharmaceutical Co., Ltd.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
• Strategic Evaluation - Provides an overview of ASKA Pharmaceutical Co., Ltd.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
• Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

• What domain does ASKA Pharmaceutical Co., Ltd. operate and what are key points about it?
• What is the product / service portfolio of ASKA Pharmaceutical Co., Ltd.?
• How has ASKA Pharmaceutical Co., Ltd. performed financially from the 2013?
• How does ASKA Pharmaceutical Co., Ltd. rank among its peers in terms of revenue and market share?
• What are ASKA Pharmaceutical Co., Ltd. strengths and weaknesses and what opportunities and threats does it face?
• What are ASKA Pharmaceutical Co., Ltd.’s main growth strategies and how successful has the company been at implementing them?
• What is the in-house technical capability of ASKA Pharmaceutical Co., Ltd.? Where does it procure / outsource it?

Reasons to buy

• Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
• Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
• 12 hour delivery time fulfilling your urgent requests as per your requirement
• On-demand customization options that can completely cater to your needs by focusing the report onto given specifics